Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

From Your Site Articles
Houston's health tech and startup ecosystem has some recent news to catch up on. Photo via Getty Images

Houston health tech startups announce exec, funding — plus more innovation news

SHORT STORIES

Houston startup founders have been moving and shaking in the local innovation ecosystem — from growing their executive boards to raising fresh grant funding.

In this roundup of Houston startup and innovation news, a startup opens a crowdfunding round, a Houston hospital system taps into new technology, and more.

Coya Therapeutics names new president and chief medical officer

Fred Grossman will assume his new role next week. Photo via LinkedIn

Coya Therapeutics Inc. (NASDAQ: COYA), a revolutionary biotech company based in Houston, named Dr. Fred Grossman as president and chief medical officer. The clinical-stage company, which has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again, announced the closing of its $15.25 million IPO in January.

According to the company, Dr. Grossman's position, which was held by Dr. Adrian Hepner, is effective July 17.

“We are grateful for Dr. Hepner’s leadership and excellence in positioning Coya and look forward to having him continue to collaborate with the company in moving our assets forward," Howard H. Berman, CEO of Coya, says in a news release. "We also welcome Dr. Grossman, who brings decades of clinical development experience and successful execution."

Dr. Grossman has held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, Sunovion, Glenmark Pharmaceuticals, and Mesoblast Inc. (NASDAQ: MESO), developing allogeneic cellular therapies for inflammatory diseases.

CellChorus receives another SBIR grant

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured additional funding. Photo via Getty Images

Fresh off a $2.3 million grant last month, Houston-based CellChorus, a single-cell analysis company, has another grant to celebrate.

The U.S. National Science Foundation has awarded CellChorus a Small Business Innovation Research (SBIR) grant to advance development of its Time-lapse Imaging Microscopy In Nanowell Grids, known as TIMING. The funding will be used to develop novel microscale arrays to support scaling dynamic single-cell analysis.

“This funding will further development of novel arrays to build on the success of our early access laboratory based in Houston,” says Mohsen Fathi, head of technology at CellChorus, in a press release. “This project will support scaling the only platform that can evaluate migration, contact dynamics, killing, survival, subcellular activity, and biomolecule secretion for the same individual cell over time and in high throughput to improve development and delivery of novel therapies.”

According to the release, the company is receiving more than $274,000 as a part of the grant, but CellChorus has the potential of receiving up to $2 million from the second phase.

“This award builds on our recent funding from the National Institute of General Medical Sciences to advance development of a dedicated instrument platform for TIMING,” says Daniel Meyer, CEO of CellChorus, in the release.

Memorial Hermann partners with TMC-backed virtual OB-GYN care

Two Houston-area hospitals now have access to this digital health startup's platform. Photo via Getty Images

The Memorial Hermann Health System has entered into a partnership with Washington, D.C.-based Babyscripts, a virtual care platform for managing obstetrics. The company is backed by the Texas Medical Center's venture fund and has existing ties to the city.

"Memorial Hermann strives to make Greater Houston a place where every woman's pregnancy, delivery and postpartum experience is successful and safe. This innovative partnership is a continuation of that commitment," says Dr. Victoria Regan, vice president of Women's and Children's Services at Memorial Hermann, in a news release.

Now, Memorial Hermann patients will be able to access Babyscripts myJourney, an app that delivers educational content, email campaigns, satisfaction surveys, appointment reminders, and more. The first two hospitals to receive access are Memorial Hermann Memorial City Medical Center and Memorial Hermann The Woodlands Medical Center, with plans to expand the program.

"The ability to access adequate prenatal and postpartum care is one of the largest predictors of maternal and infant health outcomes," says Anish Sebastian, CEO and co-founder of Babyscripts in the release. "With Babyscripts, Memorial Hermann is able to streamline the maternal health experience across their system, adding opportunities for access and providing consistent, high-quality pregnancy care to all patients, regardless of race, income, geography or risk."

Earn Your Freedom launches crowdfunding campaign with Houston nonprofit's support

Earn Your Freedom is looking for financial support from its community. Photo via houston.impacthub.net

Earn Your Freedom, a Houston startup that's gamifying personal finance education, has launched its first crowdfunding campaign in partnership with Impact Hub Houston.

The goal for EYF is to raise $100,000 to support its gaming programs with local schools. Impact Hub Houston is the fiscal sponsor for the raise, which is officially live and open for contributions.

The innovative and interactive web and mobile video game, which officially launched earlier this year to celebrate Financial Literacy Month, was designed to help kids build a strong foundation in money management, economics and investment in a fun and engaging way. It features challenges and real-world scenarios such as renting a first apartment, opening a first bank account, budgeting at the grocery store, buying stocks and index funds and renting or buying real estate.

“We envision a society where financial literacy is accessible to all, and where individuals are enabled with the tools to take control of their financial futures," says Keely McEnery, EYF co-founder and COO, in a press release. "We are bridging the gap between education and application, stepping in before the real-world consequences take place.”

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured fresh funding. Photo via Getty Images

Houston biotech startup secures $2.3M grant

cha-ching

They say it’s all in the timing. For CellChorus, it’s all in the TIMING. That’s Time-lapse Imaging Microscopy In Nanowell Grids. TIMING is a visual AI program that evaluates cell activation, killing and movement, which allows scientists to better understand how cells function.

The technology is important to the development of novel therapies in the realms of oncology, infectious diseases, and countless other disorders and diseases. By allowing scientists to observe those maladies at their roots, it will enable them to create, and ultimately deliver new medications and other therapies faster, at lower cost, and with a higher success rate.

CellChorus is a spinoff of the Single Cell Lab at the University of Houston. Part of UH’s Technology Bridge, CEO Daniel Meyer connected with co-founder and leader of Single Cell Lab, Navin Varadarajan, through co-founder Laurence Cooper.

“The company had been established, but there were limited operations,” recalls Meyer during a phone call with InnovationMap.

That was the fall of 2020. Now, the team has just announced a $2.3 million SBIR (Small Business Innovation Research) Fast-Track grant from the National Institute of General Medical Sciences.

“This funding will support development of a product offering that builds on the success of our early access laboratory,” Cooper said in a press release. “As the next frontier of cellular analysis, dynamic single-cell analysis will increase the impact that immunotherapies have in improving the lives of patients.”

Meyer is based in the Bay Area, but the rest of the team is in Houston. Meyer has a proven track record as an investor and early stage entrepreneur in life sciences companies, including work as COO of Genospace, which was acquired by HCA Healthcare.

Meyer says that what attracted him to CellChorus was a combination of a clear need for the technology and the fact that it was “very well validated.“

“Developers of immunotherapies need better functional data earlier so that they can develop and deliver better therapies,” he explains.

Another aspect of its appeal was the fact that more than 10 publications featured data from the TIMING platform.

“We’ve had both large and small biopharmas publish data,” says Meyer. “That’s important as well because it shows there’s applicability in both nonprofit and for-profit research.”

Though Meyer himself doesn’t currently live in Houston, he recognizes its importance to CellChorus. He says that it can be difficult for an early stage company to find appropriate lab space, so Technology Bridge was of exceptional importance for CellChorus. Since opening the lab a year and a half ago, Varadarajan and his team have been busy.

“Example projects we have completed include understanding mechanism of action for cell therapy products, selecting lead candidates for T cell engagers, identifying biomarkers of response to cell therapies, and quantifying potency and viability for cell therapy manufacturing technologies,” says Meyer.

And now, CellChorus is collaborating with leaders in the industry.

“These include top-25 biopharmaceutical companies and promising venture-backed biotechnology companies, as well as leading not-for-profit research institutions,” says Meyer in a press release. It’s clear that the TIMING is right for CellChorus to excel.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.

Axiom Space tops $525M in oversubscribed round, announces Swiss subsidiary

funding boost

Axiom Space tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million.

Axiom shared in February that it had secured $350 million in a financing round led by Type One Ventures and Qatar Investment Authority. In the latest release from the company, Axiom reports that Japan-based MUFG Bank Ltd. joined the round as a new investor, in addition to continued participation from existing backers.

The funding will go toward developing the company's commercial space station, known as Axiom Station, and the production of its Axiom Extravehicular Mobility Unit (AxEMU) under its NASA spacesuit contract.

“Investor interest in this round outpaced what we set out to raise, which speaks to the moment we’re in,” Jonathan Cirtain, CEO and president of Axiom Space, said in the news release. “Our partners see what is possible in low-Earth orbit, and they see who is positioned to lead it.”

Axiom announced last month that it planned to open a Japanese subsidiary July 1. Earlier this week, it also shared plans to establish Axiom Space Switzerland, a wholly owned subsidiary based in Lucerne that is also expected to begin operations this summer.

The Switzerland subsidiary aims to establish Axiom's presence in Europe and help it partner with the European Space Agency and other space organizations and companies on the continent.

“Europe is a founding leader in the creation of the commercial space economy, and Switzerland is uniquely positioned to convene the government agencies, research institutions, and industrial entities that will shape its next decade,” Cirtain added in a separate release. “Axiom Space Switzerland facilitates the scaling of development and deployment of the infrastructure that will succeed the International Space Station.”

Texas cashes in among 10 best U.S. state economies in 2026 report

State Economics

A new study gauging the success or decline in economic performance in every state has revealed Texas' economy remains stable in 2026 after it dropped out of the top five to No. 8 last year.

Texas boasts the No. 8 best state economy in the U.S. this year, according to WalletHub's annual "Best & Worst State Economies" report. The personal finance website's analysts ranked all 50 states and the District of Columbia across 28 relevant metrics to measure each state's economic activity and health status, and its "innovation potential."

Notably, Texas leads the nation for the most exports per capita in the U.S. in a five-way tie with Louisiana, Kentucky, North Dakota, and Indiana. Across the study's three main categories, Texas ranked highly for its economic activity (No. 7) and economic health (No. 11), and the state's "innovation potential" rank is the 24th best in the nation.

This is how WalletHub ranked Texas' economic performance, where No. 1 is considered the best and No. 25 is considered average:
  • No. 6 – Change in non-farm payrolls
  • No. 8 – Change in GDP
  • No. 8 – Startup activity
  • No. 11 – Annual median household income
  • No. 18 – Government surplus/deficit per capita
  • No. 21 – Percentage of jobs in high-tech industries
  • No. 30 – Unemployment rate
WalletHub previously ranked Texas one of the top three states to start a business in 2026, with Houston earning its own entrepreneurial acclaim in separate rankings of the best big cities for new businesses and for starting a career.

"U.S. economic growth depends heavily on the performance of individual states, and some contribute more than others," the report's author wrote. "For example, California, Texas, New York and Florida have economies so large that if they were countries, they would rank in the top 20 in the world."

The five states with the worst state economies in 2026 are Rhode Island (No. 47), Maine (No. 48), Louisana (No. 49), Kentucky (No. 50), and West Virginia (No. 51).

The top 10 best state economies for 2026 are:

  • No. 1 – Massachusetts
  • No. 2 – Washington
  • No. 3 – Utah
  • No. 4 – California
  • No. 5 – Delaware
  • No. 6 – North Carolina
  • No. 7 – New York
  • No. 8 – Texas
  • No. 9 – Colorado
  • No. 10 – Florida

---

This article originally appeared on CultureMap.com.

View All Listings